Compound Detail
CHEMBL2218896
NABILONE 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
Basic Information
| ChEMBL ID | CHEMBL2218896 |
| Name | NABILONE |
| Phase | Approved |
| Structure Type | MOL |
| InChI Key | GECBBEABIDMGGL-UHFFFAOYSA-N |
| Therapeutic | ✓ Yes |
4
Targets
13
Activities
2
Assay Types
0
PK Parameters
20
Publications
5
Known Names
13
Indications
1
Mechanisms
Molecular Properties
372.6
MW (Da)
6.26
ALogP
3
HBA
1
HBD
46.5
PSA (Ų)
0.60
QED
1
Ro5 Violations
6
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| First Approval | 1985 |
| Availability | Discontinued |
| Chirality | Racemic |
Mechanism of Action
| Mechanism | Action Type | Target | Direct | Efficacy |
|---|---|---|---|---|
| Cannabinoid CB1 receptor agonist | AGONIST | Cannabinoid receptor 1 | ✓ | ✓ |
Indications
Nausea Neoplasms Postoperative Nausea and Vomiting Postoperative Nausea and Vomiting Diabetic Neuropathies Parkinson Disease Fibromyalgia Marijuana Abuse Muscle Spasticity Neuralgia Obesity Suicidal Ideation Obsessive-Compulsive Disorder
ATC Classification
A04AD11
nabilone
Level 1: ALIMENTARY TRACT AND METABOLISM
Level 2: ANTIEMETICS AND ANTINAUSEANTS
Activity Summary
Ki 10 meas. best 8.74
EC50 3 meas. best 8.4
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| Cannabinoid receptor 2 CHEMBL5373 | Ki | 8.74 | 8.74 | 1.8 | 1 |
| Cannabinoid receptor 2 CHEMBL253 | Ki | 8.73 | 8.3525 | 1.8 | 4 |
| Cannabinoid receptor 1 CHEMBL218 | Ki | 8.66 | 8.5025 | 2.2 | 4 |
| Cannabinoid receptor 1 CHEMBL3571 | Ki | 8.66 | 8.66 | 2.2 | 1 |
| Cannabinoid receptor 1 CHEMBL218 | EC50 | 8.4 | 8.4 | 4.0 | 2 |
| Cannabinoid receptor 2 CHEMBL253 | EC50 | 7.8 | 7.8 | 15.8 | 1 |
Activity Data Samples
Top measurements by pChEMBL value
Literature References
| PubMed | DOI | Target Context | # Activities |
|---|---|---|---|
| 16472241 | 10.2174/1570163043334794 | Hepatotoxicity | 18 |
| 22194678 | 10.1371/journal.pcbi.1002310 | Hepatotoxicity | 14 |
| - | 10.6019/CHEMBL4651402 | SARS-CoV-2 | 4 |
| 21885167 | 10.1016/j.ejmech.2011.08.021 | No relevant target | 4 |
| 37468498 | 10.1038/s41467-023-40064-9 | Histamine H1 receptor | 3 |
| 21885167 | 10.1016/j.ejmech.2011.08.021 | Cannabinoid receptor 1 | 2 |
| - | 10.6019/CHEMBL4651402 | Vero C1008 | 2 |
| 26948801 | 10.1016/j.drudis.2016.02.015 | Homo sapiens | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Peroxisome proliferator-activated receptor gamma | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Gamma-aminobutyric acid receptor subunit alpha-1 | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Muscarinic acetylcholine receptor M2 | 2 |
| 21885167 | 10.1016/j.ejmech.2011.08.021 | Cannabinoid receptor 2 | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Alpha-1A adrenergic receptor | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Alpha-2A adrenergic receptor | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | D(1A) dopamine receptor | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Nuclear receptor subfamily 1 group I member 2 | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Progesterone receptor | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Gamma-aminobutyric acid receptor subunit alpha-1/alpha-2/beta-2/gamma-2 | 2 |
| 20688519 | 10.1016/j.bmcl.2010.07.056 | Cannabinoid receptor 1 | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | 5-hydroxytryptamine receptor 1A | 2 |
Data from ChEMBL 36 via Core Engine